NDA 214916 · Vifor Intl
Korsuva
Difelikefalin Acetate · Intravenous
NovelBreakthrough therapyPriority reviewCDER novel approval, Aug 23, 2021: To treat moderate-to-severe pruritus associated with chronic kidney disease in certain populations
Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Aug 23, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
22
11 Phase 3, 1 recruiting
FAERS reports
413
297 serious, 64 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 26, 2025.
KORSUVA is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). KORSUVA is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). ( 1 ) Limitation of Use Korsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population. ( 1 ) Limitations of Use KORSUVA has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.
Mechanism: KORSUVA is a kappa opioid receptor (KOR) agonist. The relevance of KOR activation to therapeutic effectiveness is not known.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 23, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
- KORSUVA · DIFELIKEFALIN ACETATE EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Difelikefalin" as an intervention, any sponsor and status, largest first.
- A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or KneePivotal-lookingCompleted
Cara Therapeutics, Inc.Industry
NCT02944448 · 761 participants · Start Sep 2016 · Primary completion May 2017
Drug: CR845 tablet 1 mg; CR845 tablet 2.5 mg and 2 more · For: Osteoarthritis, Hip; Osteoarthritis, Knee; Arthritis and 3 more
Sites: Birmingham, Alabama; Peoria, Arizona; Phoenix, Arizona · 35 sites in all
- CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusPivotal-lookingCompleted
Cara Therapeutics, Inc.Industry
NCT03636269 · 473 participants · Start Jul 17, 2018 · Primary completion Mar 30, 2020
Drug: CR845 0.5 mcg/kg; Placebo · For: Uremic Pruritus
Sites: Chula Vista, California; Fountain Valley, California; Northridge, California · 92 sites in all
- A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal SurgeryPivotal-lookingCompleted
Cara Therapeutics, Inc.Industry
NCT02542384 · 451 participants · Start Sep 2015 · Primary completion Apr 2018
Drug: CR845 IV 1 mcg/kg; CR845 IV 0.5 mcg/kg and 1 more · For: Post Abdominal Surgery Pain
Sites: Sheffield, Alabama; New Haven, Connecticut; Bradenton, Florida · 23 sites in all
- Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic DermatitisPivotal-lookingCompleted
Cara Therapeutics, Inc.Industry
NCT04018027 · 401 participants · Start Jun 29, 2019 · Primary completion Apr 1, 2021
Drug: difelikefalin 0.25 mg; difelikefalin 0.5 mg and 2 more · For: Pruritus; Atopic Dermatitis
Sites: Anniston, Alabama; Birmingham, Alabama; Scottsdale, Arizona · 40 sites in all
- A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)Pivotal-lookingCompleted
Cara Therapeutics, Inc.Industry
NCT03422653 · 378 participants · Start Feb 20, 2018 · Primary completion Apr 6, 2019
Drug: CR845 0.5 mcg/kg; Placebo · For: Uremic Pruritus
Sites: Homewood, Alabama; Huntsville, Alabama; Bakersfield, California · 57 sites in all
- Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusPivotal-lookingCompleted
Cara Therapeutics, Inc.Industry
NCT03281538 · 288 participants · Start Aug 14, 2017 · Primary completion Feb 11, 2020
Drug: CR845 · For: Uremic Pruritus
Sites: Chula Vista, California; El Centro, California; Long Beach, California · 27 sites in all
- Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic DermatitisPivotal-lookingTerminated
Cara Therapeutics, Inc.Industry
NCT05387707 · 287 participants · Start Aug 16, 2022 · Primary completion Feb 2, 2024
Drug: difelikefalin 0.25 mg; difelikefalin 0.5 mg and 3 more · For: Pruritus; Atopic Dermatitis
Sites: Scottsdale, Arizona; Fort Smith, Arkansas; Rogers, Arkansas · 61 sites in all
- A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusPivotal-lookingTerminated
Cara Therapeutics, Inc.Industry
NCT05342623 · 286 participants · Start May 17, 2022 · Primary completion Feb 29, 2024
Drug: Difelikefalin 1 mg Oral Tablet; Placebo Oral Tablet · For: Chronic Kidney Diseases; Pruritus
Sites: Huntsville, Alabama; Phoenix, Arizona; Surprise, Arizona · 83 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness45
- somnolence40
- fall35
- death30
- drug ineffective24
- mental status changes23
- confusional state19
- asthenia18
- nausea18
- off label use17
- pruritus17
- hallucination16
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 61 |
| 2023 | 124 |
| 2024 | 83 |
| 2025 | 102 |
| 2026 | 43 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
Fishbane S, Jamal A, Munera C, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Pharmacological interventions for pruritus in adult palliative care patients.
Boehlke C, Joos L, Coune B, et al. · Cochrane Database Syst Rev 2023 · Meta-Analysis, Systematic Review
- Difelikefalin for Hemodialysis Patients with Pruritus in Japan.
Narita I, Tsubakihara Y, Takahashi N, et al. · NEJM Evid 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.
Weiner DE, Schaufler T, McCafferty K, et al. · Nephrol Dial Transplant 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Difelikefalin in the treatment of hemodialysis patients with pruritus: a systematic review and meta-analysis.
Cai X, Wu G, Lin Y, et al. · Front Pharmacol 2024 · Systematic Review
- The efficacy and safety of difelikefalin for pruritus in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials.
Saeed A, Elshnoudy IA, Khlidj Y, et al. · Ren Fail 2024 · Systematic Review, Meta-Analysis
Sponsor: Vifor Intl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.